Cadila Pharmaceuticals

Cadila Pharma remains committed to translating groundbreaking science into real benefits for patients worldwide. Our investment in advanced R&D and next-generation vaccine technologies, such as the three-dose rabies regimen (ThRabis) and the VLP-based influenza vaccine (Cadiflu Tetra), highlights our dedication to innovation and patient wellbeing.

Persistent global challenges remain, notably rabies, seasonal influenza, and the continuous emergence of novel viral threats. Seasonal influenza is a recurrent, widespread, and debilitating viral infection. The World Health Organization (WHO) estimates that seasonal influenza causes 290,000 to 650,000 deaths from respiratory diseases globally each year.

India continues to face an exceptionally high burden of preventable infectious diseases, making the expansion of vaccination coverage an imperative national priority. Rabies presents a significant challenge. Rabies causes approximately 59,000 deaths globally each year, with India alone accounting for an estimated 36% of global rabies fatalities.

Expanding vaccination coverage, advancing indigenous innovation, and improving accessibility to life-saving vaccines across diverse populations are crucial next steps in the fight against these preventable diseases.

Portfolio highlights: Next-generation 
vaccine solutions

We deliver key innovations in the vaccine landscape, designed to enhance protection, streamline regimens, and improve patient compliance in high-burden regions.

Cadila Pharma is the manufacturer of ThRabis, reportedly the world’s first three-dose rabies vaccine.

The anti-rabies vaccine revolution

The Cadiflu Tetra Vaccine is an advanced Quadrivalent Influenza Vaccine launched in 2024. The DCGI approves it for use in adults and children.

Advanced influenza protection

Brand names are for reference purpose only and shall not be treated as an advertisement. Please consult a registered medical practitioner before taking any medication.

downWhiteCurveArrow

Corporate Identification No : U24231GJ1991PLC015132

©2026 Cadila Pharmaceuticals. All rights reserved